Drugs /

s-equol

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable, non-steroidal estrogen naturally produced by the metabolism of the isoflavonoid daidzein by human intestinal microflora, with potential chemoprotective and estrogen receptor (ER) modulating activities. S-equol preferentially binds to and activates the beta isoform of ER in certain target tissues, while having an antagonistic effect in other tissues. This modulates the expression of ER-responsive genes in a tissue-specific manner. This agent may increase bone mineral density, affect vasomotor symptoms, and may decrease the proliferation rate of susceptible cancer cells. In addition, this agent interferes with the activity of enzymes involved in steroid biosynthesis. S-equol inhibits dihydrotestosterone (DHT) production and may inhibit the proliferation of androgen-driven prostate cancer. S-equol is the biologically active enantiomer while R-equol is essentially inactive and has a weak affinity for alpha-ER.

Clinical Trials

View Clinical Trials for s-equol

S-equol has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating s-equol, 1 is early phase 1 (0 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for s-equol clinical trials.

Breast carcinoma is the most common disease being investigated in s-equol clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating S-Equol
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating s-equol and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
(-)-equol, equol, (-)-, 531-95-3, (3s)-3,4-dihydro-3-(4-hydroxyphenyl)-2h-1-benzopyran-7-ol, (-)-equol, equol, (-)-, 2h-1-benzopyran-7-ol, 3,4-dihydro-3-(4-hydroxyphenyl)-, (3s)-, 2h-1-benzopyran-7-ol, 3,4-dihydro-3-(4-hydroxyphenyl)-, (3s)-
NCIT ID [1]:
C120313

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.